Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability, Mass Balance, PK, Metabolism, and Excretion of [14C]VH4524184 in Healthy Participants
NCT07636928Phase 1Recruiting
- Sponsor
- ViiV Healthcare
- Start
- Jun 2026
- Primary completion
- Aug 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of VH4524184 in human immunodeficiency virus infection (HIV), sponsored by ViiV Healthcare. Primary endpoints: Absolute bioavailability, Amount of total radioactivity excreted in urine and 12 more. Started Jun 2026; status: recruiting.
02
Drugs
VH4524184
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07636928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07636928.